Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 2/20 | 0.31 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.31 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.31 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.31 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.31 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19548893 | 0.82 | — | — | |
| SCHEMBL17961705 | 0.76 | — | — | |
| SCHEMBL28683041 | 0.68 | — | — | |
| SCHEMBL19548927 | 0.68 | CYP2D6 (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1960138 | 0.64 | — | — | |
| SCHEMBL21617649 | 0.64 | KDM4E (0.35) | — | |
| SCHEMBL21617651 | 0.64 | KDM4E (0.35) | — | |
| SCHEMBL1399146 | 0.64 | — | — | |
| SCHEMBL19205899 | 0.64 | TP53 (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL25417100 | 0.64 | CTSK (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10912755-B2 | Arginase inhibitors and their therapeutic applications | Oncoarendi Therapeutics S.A. (PL) | 2021-02-09 | — | — | US | disclosed |
| EP-3452485-B1 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | ONCOARENDI THERAPEUTICS SA (PL) | 2020-09-09 | — | — | EP | disclosed |
| US-10391077-B2 | Arginase inhibitors and their therapeutic applications | Oncoarendi Therapeutics S.A. (PL) | 2019-08-27 | — | — | US | disclosed |
| EP-3452485-A2 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | Oncoarendi Therapeutics SA (PL) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017191130-A2 | ARGINASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | ONCOARENDI THERAPEUTICS SA (PL) | 2017-11-09 | — | — | WO | disclosed |
| US-20170319536-A1 | Arginase Inhibitors and Their Therapeutic Applications | Oncoarendi Therapeutics S.A. (PL) | 2017-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10391077-B2 | Arginase inhibitors and their therapeutic applications | ARG1, ARG2, ARGLU1 | PSEN1 3623/4885PSEN2 3293/4885APH1B 1165/4885 |
| US-20170319536-A1 | Arginase Inhibitors and Their Therapeutic Applications | ARG1, ARG2, ARGLU1 | PSEN1 3623/4885PSEN2 3293/4885APH1B 1165/4885 |
| US-10912755-B2 | Arginase inhibitors and their therapeutic applications | ARG1, ARG2, ARGLU1 | PSEN1 3623/4885PSEN2 3293/4885APH1B 1165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.